Omeros (OMER) PT Set at $30.00 by HC Wainwright
Omeros (NASDAQ:OMER) has been given a $30.00 price objective by equities researchers at HC Wainwright in a report released on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 53.37% from the stock’s previous close.
Several other research firms have also weighed in on OMER. Cantor Fitzgerald restated a “hold” rating and set a $19.00 target price (up from $15.00) on shares of Omeros in a report on Thursday, August 24th. Zacks Investment Research upgraded Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th. Wedbush reiterated an “outperform” rating and issued a $47.00 price objective on shares of Omeros in a research note on Tuesday, November 28th. Maxim Group reiterated a “buy” rating and issued a $24.00 price objective on shares of Omeros in a research note on Monday, November 6th. Finally, Cowen lowered Omeros from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 2nd. Five analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $34.14.
Omeros (OMER) opened at $19.56 on Thursday. Omeros has a 1-year low of $8.71 and a 1-year high of $27.09. The company has a quick ratio of 4.74, a current ratio of 4.77 and a debt-to-equity ratio of 8.99.
Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.18. The company had revenue of $21.66 million for the quarter, compared to the consensus estimate of $17.82 million. During the same quarter last year, the business earned ($0.34) earnings per share. Omeros’s quarterly revenue was up 91.9% on a year-over-year basis. research analysts predict that Omeros will post -0.98 earnings per share for the current year.
A number of hedge funds have recently added to or reduced their stakes in OMER. First Interstate Bank acquired a new stake in Omeros during the third quarter worth about $108,000. Legal & General Group Plc grew its position in Omeros by 7.8% during the second quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 751 shares in the last quarter. Hanseatic Management Services Inc. grew its position in Omeros by 10,919.6% during the third quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 10,592 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new stake in Omeros during the third quarter worth about $256,000. Finally, SG Americas Securities LLC grew its position in Omeros by 138.9% during the third quarter. SG Americas Securities LLC now owns 12,154 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 7,067 shares in the last quarter. 49.85% of the stock is currently owned by institutional investors and hedge funds.
Omeros Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with Analyst Ratings Network's FREE daily email newsletter.